Departement of Medicine, Division of Hematology and Translational Research Laboratory in Cell Therapy, 39 rue Camille Desmoulins 94805 Villejuif Cedex France
- Key words: chronic myelogenous leukemia, Bcr-Abl, imatinib mesylate, tyrosine kinase
- Page(s) : 75-82
- Published in: 2005
The introduction of imatinib mesylate (IM) has revolutionized the therapy of chronic myelogenous leukemia (CML) and changed dramatically the therapeutic strategies in this malignant disease. After the establishment of its success in patients refractory to standard treatments, IM has shown its superiority in terms of cytogenetic response in previously untreated patients and became the first line therapy in the majority of patients with CML. However, it is currently unknown if IM will have a curative potential in CML, a potential which has been shown only for allogeneic stem cell transplantation to date. The recent description of the development of resistance to IM and the discovery of the underlying Abl-kinase mutations as a principal mechanism of resistance prompted a major research effort to understand the pathophysiology of the resistance phenomenon and stimulated the implementation of new algorithms for the treatment.